JAP15 Rec'd PCT/PTO 21 FEB 2007

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

6. ²

	ANSMITTAL LETTER TO	ATTORNEY'S DOCKET NUMBER PP020110.0005/59516-313				
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5)			
	10/566,410 PRIORITY DATE CLAIMED					
PCT/US	TIONAL APPLICATION NO. 2004/017921	INTERNATIONAL FILING DATE 04 June 2004 (04.06.2004)	30 July 2003 (30.07.2003)			
TITLE OF	INVENTION METHODS OF THERA	APY FOR CHRONIC LYMPHOCYTIC LE	EUKEMIA			
	NT(S) FOR DO/EO/US Deborah HURS					
Applicant	herewith submits to the United Sta	ates Designated/Elected Office (DO/EC	O/US) the following items and other information:			
1.	This is a FIRST submission of items co	oncerning a submission under 35 U.S.C. 371	l.			
2. 🔽 1	This is a SECOND or SUBSEQUENT s	submission of items concerning a submissio	n under 35 U.S.C. 371.			
3. 🗸 1	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.					
4. 🗸	The US has been elected (Article 31).					
5. 🗸	A copy of the International Application	n as filed (35 U.S.C. 371(c)(2))				
	a. is attached hereto (required	d only if not communicated by the Internation	nal Bureau).			
	b. has been communicated by the International Bureau.					
	c. s is not required, as the application was filed in the United States Receiving Office (RO/US).					
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).					
	a. is attached hereto.					
	b. has been previously submitted under 35 U.S.C. 154(d)(4).					
7. 🗸	Amendments to the claims of the Inte	ernational Application under PCT Article 19	(35 U.S.C. 371(c)(3))			
	a. are attached hereto (requi	ired only if not communicated by the Interna	tional Bureau).			
	b. have been communicated by the International Bureau.					
	c. have not been made; how	vever, the time limit for making such amendr	nents has NOT expired.			
	d. have not been made and	will not be made.				
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).					
9. 🗸	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
10.	An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items	Items 11 to 20 below concern document(s) or information included:					
11. 🔲	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.				
12. 🔲	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.					
13. 🗸	A preliminary amendment.					
14. 🗸	An Application Data Sheet under 37 CFR 1.76.					
15. 🔲	A substitute specification.					
16. 🗌	A power of attorney and/or change of address letter.					
17. 🔲	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.					
18.	A second copy of the published International Application under 35 U.S.C. 154(d)(4).					
19.	A second copy of the English langua	ge translation of the international application	n under 35 U.S.C. 154(d)(4).			
i						

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007, OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	10/566,410	TON NO. (if known	, see 37 CFR 1.5)	PCT/US2004/017921	PLICATION NO.	PP020110.0005/59516	
	20. Other items or information:						
	Copy of 371 Formalities Letter; Petition Under 37 CFR 1.47(a); Declaration of Lisa Nash w/Exhbits A-D; Petition for Extension of Time (+ copy); Petition Fee Transmittal (+ copy); Statement in Response to Sequence Requirement; return receipt postcard						
ŀ	The following fees have been submitted					CALCULATIONS	PTO USE ONLY
	21. Basic	c national fee (37	CFR 1.492(a))		\$300	\$	
	22.	22. Examination fee (37 CFR 1.492(c))					
	by IPFA/I	IS indicates all cl	aims satisfy provi	national preliminary examina sions of PCT Article 33(1)-(4)	50	\$	
	If the written opini IPEA/US Search fee (37 Ci Internatio International Sea	indicates all clain FR 1.445(a)(2)) hand Searching Au rch Report prepar communicated to	or the Internation is satisfy provision as been paid on the thorityed by an ISA other the US by the IB	al preliminary examination rens of PCT Article 33(1)-(4)ne international application to the rent the US and provided to the second sec	\$0 the USPTO as an\$100 o the Office or \$400	\$	
						\$0	
	Additional fee sequence electronic	total of 21, 22 and 23 = ditional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
	Total Sheets	Extra Sheets		additional 50 or fraction up to a whole number)	RATE		
	- 100 =	/50 =			x \$250	\$	·
	Surcharge of \$13 after the date of c	e of \$130.00 for furnishing any of the search fee, examination fee, or the oath or date of commencement of the national stage (37 CFR 1.492(h)).		oath or declaration	\$ 130.00		
	CLAIMS	NUME	ER FILED	NUMBER EXTRA	RATE	\$	
	Total claims		32 - 20 =	12	x \$50	\$ 600.0	0
	Independent clair	ns	7 -3=	4	x \$200	\$ 800.0	0
ı	MULTIPLE DEPE	NDENT CLAIM(S	S) (if applicable)		+ \$360	\$ 0.0	0
			\$ 1400.0	0			
Ì	Applicant cla	ims small entity s	tatus. See 37 CFF	R 1.27. Fees above are redu			
					SUBTOTAL :	1000.00	
	Processing fee of claimed priority d			translation later than 30 mon	ths from the earliest	\$ 0.00	
	TOTAL NATIONAL FEE =					\$ 1530.00	
	Fee for recording by an appropriate	the enclosed ass cover sheet (37	ignment (37 CFR CFR 3.28, 3.31).	1.21(h)). The assignment mu \$40.00 per property	ust be accompanied +	\$ 0.00	
)7	LANDGRA 000000	03 040258 1	0566410	TOTAL F	EES ENCLOSED		
7	130.00 I					Amount to be refunded:	\$
14	800.00 1	72.5				Amount to be charged	\$

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$	to cover the above fees is enclosed.				
b. Please charge my Deposit Ac A duplicate copy of this sheet	count No. 04-0258 in the amount of \$ 1530.00 to cover the above fees. is enclosed.				
c. The Commissioner is hereby a Account No. <u>04-0258</u> . A	uthorized to charge any additional fees which may be required, or credit any overpayment to Deposit duplicate copy of this sheet is enclosed.				
d. Fees are to be charged to a cr be included on this form. Pro	edit card. WARNING : Information on this form may become public. Credit card information should not wide credit card information and authorization on PTO-2038.				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO: Davis Wright Tremaine LLP 2600 Century Square 1501 Fourth Avenue Seattle, Washington 98101-1688 UNITED STATES OF AMERICA Phone: (206) 622-3150 Facsimile: (206) 628-7699	SIGNATURE Jane E.R. Potter NAME 33,332 REGISTRATION NUMBER				



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Sox 1459 Alexandria, Virginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICAN	T ATTY. DOCKET NO).		
10/566,410	Deborah Hurst	PP02011000055951	6313		
		INTERNATIONAL APPLICATION NO).		
		PCT/US04/17921	PCT/US04/17921		
Davis Wright Tremaine		I.A. FILING DATE PRIORITY	/ DATE		
2600 Century Square	RECEIVED	06/04/2004 07/30/	2003		

Seatle, WA 98101-1688

JUL 2 5 2006

CONFIRMATION NO. 5534 371 FORMALITIES LETTER

OC000000019708608

Date Mailed: 07/21/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 01/30/2006
- Copy of the International Search Report filed on 01/30/2006
- U.S. Basic National Fees filed on 01/30/2006
- Priority Documents filed on 01/30/2006
- Specification filed on 01/30/2006
- Claims filed on 01/30/2006
- Abstracts filed on 01/30/2006
- Drawings filed on 01/30/2006

ENTERED IN DWT

JUL 2 6 2006

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Additional claim fees of \$960 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.
- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$1090 for a Large Entity:

- \$130 Surcharge.
 - This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- Total additional claim fee(s) for this application is \$ 960
 - **\$600** for **31** total claims over 20.
 - \$360 for multiple dependent claim surchare.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/566,410	PCT/US04/17921	PP020110000559516313

FORM PCT/DO/EO/905 (371 Formalities Notice)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Deborah Hurst et al.

Application No.

10/566,410 (U.S. National Phase of PCT/US04/17921)

§ 371 Date

January 30, 2006

For

METHODS OF THERAPY FOR CHRONIC LYMPHOCYTIC

LEUKEMIA

Docket No. :

59516-313

Date

February 21, 2007

MS PCT **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

STATEMENT IN RESPONSE TO SEQUENCE REQUIREMENT

Commissioner for Patents:

Applicants submit that no Sequence Listing is required for this application. 37 C.F.R. § 1.821(a) defines a sequence, in part, as four or more amino acids, or ten or more nucleotides. Applicants request that the Patent Office indicate where in the application such sequences appear. No Sequence Listing was filed with the International application because applicants believed that the specification does not contain sequence disclosure that falls within the requirements of 37 C.F.R. § 1.821(a).

> Respectfully submitted, Davis Wright Tremaine LLP

Ør. Jane E.R. Potter, Esq. Registration No. 33,332

2600 Century Square 1501 Fourth Avenue Seattle, WA 98101-1688 Phone: (206) 622-3150

Facsimile: (206) 628-7699